Treatment of Primary Aldosteronism and Organ Protection
Primary aldosteronism is a frequent form of secondary hypertension that had long been considered relatively benign. Experimental and clinical evidence collected in the last two decades, however, has clearly demonstrated that this endocrine disorder is associated with excess cardiovascular and renal...
Saved in:
| Main Authors: | , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2015-01-01
|
| Series: | International Journal of Endocrinology |
| Online Access: | http://dx.doi.org/10.1155/2015/597247 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1849473127656980480 |
|---|---|
| author | Cristiana Catena GianLuca Colussi Leonardo A. Sechi |
| author_facet | Cristiana Catena GianLuca Colussi Leonardo A. Sechi |
| author_sort | Cristiana Catena |
| collection | DOAJ |
| description | Primary aldosteronism is a frequent form of secondary hypertension that had long been considered relatively benign. Experimental and clinical evidence collected in the last two decades, however, has clearly demonstrated that this endocrine disorder is associated with excess cardiovascular and renal complications as compared to essential hypertension. These complications reflect the ability of inappropriate elevation of plasma aldosterone to cause tissue damage beyond that induced by high blood pressure itself, thereby setting the stage for major cardiovascular and renal disease. Because of the impact of elevated aldosterone on organ damage, goals of treatment in patients with primary aldosteronism should not be limited to normalization of blood pressure, and prevention or correction of organ complications is mandatory. Treatment with mineralocorticoid receptor antagonists or unilateral adrenalectomy is the respective options for treatment of idiopathic adrenal hyperplasia or aldosterone-producing adenoma. Last years have witnessed a rapid growth in knowledge concerning the effects of these treatments on cardiovascular and renal protection. This paper is an overview of the cardiovascular and renal complications that occur in patients with primary aldosteronism and a summary of the results that have been obtained in the long term on cardiovascular and renal outcomes with either medical or surgical treatment. |
| format | Article |
| id | doaj-art-d8da109928eb42559d340d3cbdaec6d6 |
| institution | Kabale University |
| issn | 1687-8337 1687-8345 |
| language | English |
| publishDate | 2015-01-01 |
| publisher | Wiley |
| record_format | Article |
| series | International Journal of Endocrinology |
| spelling | doaj-art-d8da109928eb42559d340d3cbdaec6d62025-08-20T03:24:16ZengWileyInternational Journal of Endocrinology1687-83371687-83452015-01-01201510.1155/2015/597247597247Treatment of Primary Aldosteronism and Organ ProtectionCristiana Catena0GianLuca Colussi1Leonardo A. Sechi2Hypertension Unit, Internal Medicine, Department of Experimental and Clinical Medical Sciences, University of Udine, 33100 Udine, ItalyHypertension Unit, Internal Medicine, Department of Experimental and Clinical Medical Sciences, University of Udine, 33100 Udine, ItalyHypertension Unit, Internal Medicine, Department of Experimental and Clinical Medical Sciences, University of Udine, 33100 Udine, ItalyPrimary aldosteronism is a frequent form of secondary hypertension that had long been considered relatively benign. Experimental and clinical evidence collected in the last two decades, however, has clearly demonstrated that this endocrine disorder is associated with excess cardiovascular and renal complications as compared to essential hypertension. These complications reflect the ability of inappropriate elevation of plasma aldosterone to cause tissue damage beyond that induced by high blood pressure itself, thereby setting the stage for major cardiovascular and renal disease. Because of the impact of elevated aldosterone on organ damage, goals of treatment in patients with primary aldosteronism should not be limited to normalization of blood pressure, and prevention or correction of organ complications is mandatory. Treatment with mineralocorticoid receptor antagonists or unilateral adrenalectomy is the respective options for treatment of idiopathic adrenal hyperplasia or aldosterone-producing adenoma. Last years have witnessed a rapid growth in knowledge concerning the effects of these treatments on cardiovascular and renal protection. This paper is an overview of the cardiovascular and renal complications that occur in patients with primary aldosteronism and a summary of the results that have been obtained in the long term on cardiovascular and renal outcomes with either medical or surgical treatment.http://dx.doi.org/10.1155/2015/597247 |
| spellingShingle | Cristiana Catena GianLuca Colussi Leonardo A. Sechi Treatment of Primary Aldosteronism and Organ Protection International Journal of Endocrinology |
| title | Treatment of Primary Aldosteronism and Organ Protection |
| title_full | Treatment of Primary Aldosteronism and Organ Protection |
| title_fullStr | Treatment of Primary Aldosteronism and Organ Protection |
| title_full_unstemmed | Treatment of Primary Aldosteronism and Organ Protection |
| title_short | Treatment of Primary Aldosteronism and Organ Protection |
| title_sort | treatment of primary aldosteronism and organ protection |
| url | http://dx.doi.org/10.1155/2015/597247 |
| work_keys_str_mv | AT cristianacatena treatmentofprimaryaldosteronismandorganprotection AT gianlucacolussi treatmentofprimaryaldosteronismandorganprotection AT leonardoasechi treatmentofprimaryaldosteronismandorganprotection |